Back to Authors

Zamora Martinez, Ana C

Mayo Clinic

Division of Pulmonary and Sleep Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.

Citations 1

Pleuroparenchymal fibroelastosis from a rheumatologic perspective
Diaz‐Menindez, Maximiliano , VERGARA, ALEJANDRO DIAZ ARUMIR, Shing, Vivian, Harvey, Carolyn Mead, Martinez, Ana C. Zamora, Nagaraja, Vivek, Diaz Arumir Vergara, Alejandro, Mead Harvey, Carolyn, Zamora Martinez, Ana C, Harvey, Carolyn Mead, Zamora, Ana, Nagaraja, Vivek

Therapeutic Advances in Respiratory Disease | May 6, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/17534666261445202 Get It

Background: Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease (ILD) associated with systemic autoimmune rheumatic diseases (SARDs). Its clinical characteristics and outcomes in SARDs remain poorly defined. Objectives: To describe demographics, imaging patterns, and outcomes in SARD-associated PPFE. Methods: Patients diagnosed with PPFE and SARDs at Mayo Clinic (2000-2024) were included. PPFE diagnosis was confirmed by high-resolution computed tomography, and SARD diagnoses were established by rheumatologists. Results: Fifteen of 62 patients with PPFE had SARDs with majority having systemic sclerosis (SSc)(n= 7, 46%). Median age at PPFE diagnosis was 57.2 years; 80% were female; 40% were ever-smokers; 40% required supplemental oxygen; 5 had pulmonary hypertension. Coexisting ILD patterns included UIP (26.7%) and NSIP (20%). Coexisting ILD patterns included usual interstitial pneumonia (26.7%) and nonspecific interstitial pneumonia (20%). Three patients died, including two with SSc. Conclusion: Systemic sclerosis was the most frequently observed SARD among patients with PPFE, and may coexist with other ILD patterns; recognition may inform risk stratification, multidisciplinary evaluation, and longitudinal follow-up.